Cargando…
The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs—Therapeutic potential exploration in lung injury
Since 2005, GLP-1 receptor (GLP-1R) agonists (GLP-1RAs) have been developed as therapeutic agents for type 2 diabetes (T2D). GLP-1R is not only expressed in pancreatic islets but also other organs, especially the lung. However, controversy on extra-pancreatic GLP-1R expression still needs to be furt...
Autores principales: | Pang, Juan, Feng, Jia Nuo, Ling, Wenhua, Jin, Tianru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643154/ https://www.ncbi.nlm.nih.gov/pubmed/36386481 http://dx.doi.org/10.1016/j.apsb.2022.06.003 |
Ejemplares similares
-
Commentary: Can FXR serve as a potential target for COVID-19 prevention?
por: Pang, Juan, et al.
Publicado: (2023) -
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
por: Mehdi, Syed Faizan, et al.
Publicado: (2023) -
Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output
por: Liu, Junling, et al.
Publicado: (2019) -
Computational Peptide
Design Cotargeting Glucagon
and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023) -
Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)